Oral Semaglutide: A 25-Person Readout

A small prospective study followed 25 Japanese adults with type 2 diabetes for three months after they started oral semaglutide. Average reported energy intake fell from 2,032.5 to 1,618.2 kcal per day, while body weight fell from 82.1 to 78.3 kg^[1]. The result is useful because it links ordinary eating patterns with measured body composition. It cannot show that semaglutide caused every change, and the muscle findings need a careful reading.

What the researchers measured

The University of Tokyo team consecutively enrolled adults admitted for diabetes medication adjustment between November 2021 and April 2023. All participants were new to oral semaglutide. Dietitians used a food frequency questionnaire to estimate habitual intake over the previous one to two months. Body composition was measured with bioelectrical impedance analysis, which estimates fat and lean tissue from the body's electrical resistance. The team also measured handgrip strength, blood markers and self-reported step-count categories at baseline and three months^[1].

Thirty-three people consented, but eight were excluded from the final analysis. Four stopped oral semaglutide at a physician's direction, three missed follow-up, and one could not complete the second body-composition assessment. The remaining 25 had an average age of 58.3 years, 52% were women, and their average diabetes duration was eight years^[1]. Every participant started at 3 mg daily. At follow-up, 19 remained at 3 mg, five were taking 7 mg, and one was taking 14 mg. These are study observations, not dosing instructions.

Food intake fell without a macro shift

Estimated daily energy intake declined by 414.3 kcal, or about 20%, over three months. Carbohydrate, protein and fat intake in grams all fell beyond the study's statistical threshold. Their shares of total energy did not: carbohydrate moved from 52.5% to 53.7%, protein from 15.5% to 15.9%, and fat from 32.1% to 30.4%^[1]. In plain terms, participants reported eating less overall rather than replacing one macronutrient with another.

The food-group detail was selective. Reported intake met the statistical threshold for a decrease in fats and oils, seasonings and spices, and sweets and snacks. Salt intake fell from 8.9 to 7.0 g per day^[1]. Intake did not meet the statistical threshold for a change in staples such as cereals or in fish, meat, eggs, dairy, vegetables and several other groups. A prior randomized crossover study in 15 people with type 2 diabetes also found lower free-choice energy intake with oral semaglutide than placebo after 12 weeks, alongside lower intake of high-fat and sweet foods^[2]. That earlier controlled experiment supports the appetite signal, but it does not remove the confounding in this new clinical-practice cohort.

The muscle result is easy to misread

Weight fell by 3.8 kg, with body fat mass falling from 32.9 to 30.0 kg and body-fat percentage falling from 38.7% to 36.8%. Percent muscle mass rose from 57.9% to 59.7%^[1]. That percentage increase does not mean participants gained muscle. Absolute muscle mass moved from 46.5 to 45.6 kg, a decline that narrowly missed the study's statistical threshold at p=0.053. Appendicular skeletal muscle mass, the estimated lean mass in the arms and legs, fell from 21.5 to 20.5 kg. Skeletal muscle mass index also met the threshold for a decrease^[1].

Handgrip strength did not meet the statistical threshold for a change, moving from 27.7 to 28.4 kg^[1]. The authors explain the apparently mixed picture: fat declined by a larger proportion than muscle, so muscle became a larger percentage of a smaller body even as the absolute limb-muscle estimates decreased. Bioelectrical impedance is also sensitive to hydration. It is less direct than dual-energy X-ray absorptiometry, often shortened to DXA, for separating body tissues.

Blood sugar changed too

Average HbA1c, a marker of blood glucose over roughly three months, fell from 8.9% to 7.0%. Urinary albumin and several other measures also changed^[1]. A larger Japanese real-world study, PIONEER REAL Japan, followed 624 oral semaglutide users and likewise reported lower HbA1c and body weight after 34 to 44 weeks, with no new safety findings^[3]. The larger study helps place the direction of the glucose and weight findings in context, but it did not answer this paper's detailed questions about diet and body composition.

The current US prescribing information lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation among the most common adverse reactions to oral semaglutide. It also states that the medicine delays gastric emptying^[4]. The observational paper was designed around diet and body composition, not a full comparison of adverse-event rates. Readers should not use its short follow-up as a substitute for the product label or individual clinical advice. Our semaglutide regulation overview covers the wider prescription context.

What we do not know yet

This was a single-center study with no untreated control group and only 25 participants in the final analysis. Everyone received individual nutrition counselling during the hospital admission. Other diabetes medicines changed during follow-up: DPP-4 inhibitors were stopped, while use of biguanides and SGLT2 inhibitors increased^[1]. Those changes, the admission itself, recall error in the diet questionnaire, and fluid shifts that affect impedance measurements could each account for part of the result.

The study therefore supports an association: after oral semaglutide was started in this closely observed group, reported intake, weight and fat measures fell. It does not prove that the drug alone caused the dietary or body-composition changes, nor does it establish long-term muscle safety. Larger controlled studies using DXA and longer follow-up would give a firmer answer. Anyone concerned about food intake, strength or muscle loss while taking prescribed semaglutide should discuss those changes with the clinician managing their diabetes.